A new study has revealed that more lives could have been saved in the U.S. in the last three years if the Covid-19 booster vaccine was approved sooner. Researchers estimate that through June 30, 2022, the U.S. could have saved 29,000 lives among already vaccinated people.

A study of older U.S. adults led by researchers at Brown University found that the risk of negative effects of both mRNA vaccines is exceptionally low, but lowest with the Moderna vaccine.

A study has revealed that the third-dose of Covid-19 vaccines offer extended protection from Covid-19. Third and fourth doses of these vaccines have also been offered to people who are considered as high risk in the UK.

With an aim to expand its business in Asia, Biontech has acquired one of Novartis’ GMP-certified manufacturing facilities in Singapore. With this move, the company intends to establish its first mrna facility in the country.

Laboratories across the globe are making use of smart technologies such as Artificial Intelligence (AI)—in line with the ‘Industry 4.0’ concept—due to its numerous advantages as well as to keep up with today’s changing and demanding market requirements. One of the most crucial aspects of the AI technology for laboratories is its ability to analyze large sets of data and also recommend the best possible solutions for developing innovative and at times revolutionary products.

German biopharmaceutical company Biontech announced plans for the development of the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022.

The UK has become the first country in the world to approve a Covid-19 vaccine in order to combat the global pandemic. The first doses of the vaccine developed by Pfizer-Biontech will be available to the UK immediately.

The U.S. FDA has given the nod to Pfizer and Biontech to fast track two investigational mRNA-based vaccine candidates against Sars-Cov-2. Both the companies are expected to manufacture 100 million doses by the end of 2020, if it receives regulatory approval.

With an aim to protect patients detected with Covid-19 from all over the world, Pfizer and Biontech have entered into a letter of intent to create a potential vaccine for Coronavirus. Under the terms of the agreement, BNT162 – Biontech’s Covid-19 mrna vaccine programme will be fast-tracked and will enter clinical testing towards the end of April 2020.